APLM (Apollomics) Institutional Ownership : 2.06% (As of Jan. 19, 2025)

View and export this data going back to 2023. Start your Free Trial

What is Apollomics Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Apollomics's institutional ownership is 2.06%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Apollomics's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Apollomics's Float Percentage Of Total Shares Outstanding is 87.40%.

Apollomics Institutional Ownership Historical Data

The historical data trend for Apollomics's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Apollomics Institutional Ownership Chart

Apollomics Historical Data

The historical data trend for Apollomics can be seen below:

	2024-03-31	2024-04-30	2024-05-31	2024-06-30	2024-07-31	2024-08-31	2024-09-30	2024-10-31	2024-11-30	2024-12-31
Institutional Ownership	0.27	0.52	0.42	0.40	0.36	0.35	0.38	1.20	1.20	1.20

Apollomics Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

Apollomics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Apollomics Inc (NAS:APLM) » Definitions » Institutional Ownership

Comparable Companies

Traded in Other Exchanges

APLMW:USA

Address

989 East Hillsdale Boulevard, Suite 220, Foster, CA, USA, 94404

Website

https://www.apollomicsinc.com

Apollomics Inc is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company lead programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.